Generation of two isogenic sickle cell disease induced pluripotent stem cell lines from testicular fibroblasts.

Autor:	Harancher MR; Molecular Genetics and Developmental Biology Graduate Program, University of Pittsburgh School of Medicine, USA; Department of Obstetrics, Gynecology and Reproductive Sciences, Magee-Womens Research Institute, University of Pittsburgh School of Medicine, USA., Sukhwani M; Department of Obstetrics, Gynecology and Reproductive Sciences, Magee-Womens Research Institute, University of Pittsburgh School of Medicine, USA., Castro CA; Department of Obstetrics, Gynecology and Reproductive Sciences, Magee-Womens Research Institute, University of Pittsburgh School of Medicine, USA., Hsieh MH; Children's National Hospital, Washington, DC, USA., Orwig KE; Molecular Genetics and Developmental Biology Graduate Program, University of Pittsburgh School of Medicine, USA; Department of Obstetrics, Gynecology and Reproductive Sciences, Magee-Womens Research Institute, University of Pittsburgh School of Medicine, USA. Electronic address: orwigke@upmc.edu.
Jazyk:	angličtina
Zdroj:	Stem cell research [Stem Cell Res] 2023 Dec; Vol. 73, pp. 103257. Date of Electronic Publication: 2023 Nov 21.
DOI:	10.1016/j.scr.2023.103257
Abstrakt:	Curative bone marrow transplantation (BMT) therapies for sickle cell disease (SCD) can cause infertility. The Fertility Preservation Program (FPP) in Pittsburgh cryopreserves testicular tissues for SCD patients prior to BMT in anticipation that those tissues can be thawed in the future and matured to produce sperm. Here, we generated and validated two isogenic patient-derived induced pluripotent stem cell (iPSC) lines from testicular biopsy fibroblasts of a 12-year-old SCD patient. Competing Interests: Declaration of Competing Interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Kyle Orwig reports financial support was provided by National Institute of Child Health and Human Development. Kyle Orwig has patent #PCT/US2018/043948 pending to University of Pittsburgh. If there are other authors, they declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. (Copyright © 2023 The Authors. Published by Elsevier B.V. All rights reserved.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu